Introduction {#s0001}
============

Epilepsy is a complex, multifactorial neurological disease, which is mainly characterized by a predisposition to seizure recurrence.[@cit0001] About 70 million people are affected by epilepsy all over the world, and one third of them are never free of seizures even when they receive a therapy employing anti-epileptic drugs.[@cit0002] Ischemic stroke is an important cause of epilepsy, especially in elderly people.[@cit0003] In the last decades, the incidence of post-stroke epilepsy has increased due to important advances in the therapeutic management of stroke that have reduced its mortality rate in the acute phase.[@cit0004],[@cit0005] A recent investigation reported that the incidence of post-stroke seizures could reach 15.3%.[@cit0006] After stroke, epilepsy can threaten patients not only through potential physical injuries, but also through deleterious effects on the brain with stroke lesion and degenerative changes.[@cit0007] In addition, recurrent peri-infarct depolarization may harm already vulnerable tissues through further neuronal injuries caused by the additional metabolic stress.[@cit0008],[@cit0009] Epilepsy after stroke has been demonstrated to be associated with decreased survival at 30-day and 1-year time points as well as increased length of hospital stay and resource utilization.[@cit0010],[@cit0012] The importance of post-stroke epilepsy also contemplates cognitive functioning, a lower disease-specific quality-of-life, and more disability and neurological impairment.[@cit0013] Therefore, prediction and management of seizure recurrence is critical for stroke care. However, other studies did not observe any association between post-stroke seizures and long-term disability/mortality.[@cit0014],[@cit0015]

Inflammation induced by the ischemic cerebrovascular process participates in the initiation and continuation of seizures.[@cit0016],[@cit0018] Interleukin-6 (IL-6) is a pro-inflammatory cytokine and associated with cardiovascular diseases,[@cit0019],[@cit0022] suggesting its critical role in the inflammatory response to cerebral ischemia.[@cit0023] In addition, studies show that IL-6 is associated with development of seizures.[@cit0024],[@cit0026] Elevated IL-6 levels are confirmed in several different epilepsy etiologies and media.[@cit0027] However, no previous studies investigated the association between IL-6 levels and seizure recurrence in patients with the first post-ischemic stroke seizure and its value in predicting seizure recurrence. In this study, we performed the above investigation with the aim of providing a basis for clinicians to predict seizure recurrence.

Patients and Methods {#s0002}
====================

Included Patients {#s0002-s2001}
-----------------

Between March 2013 and March 2018, 2976 consecutive ischemic stroke patients were retrospectively enrolled in the Third People's Hospital of Xinjiang Uygur Autonomous Region. Among them, 209 (7.02%) patients were diagnosed with post-stroke seizure and included in this study. Data were obtained through reviewing medical records of their routine care for ischemic stroke and seizure at outpatient department visits and admission. Seizure recurrence was followed up by neurologists in all participants until March 2019. This study was conducted in accordance with the Declaration of Helsinki and received the approval of the ethics committee of the Third People's Hospital of Xinjiang Uygur Autonomous Region (20130241018), and each participant provided written informed consent.

Inclusion and Exclusion Criteria of Included Patients {#s0002-s2002}
-----------------------------------------------------

Inclusion criteria included 1) patients with first-ever ischemic stroke which was definitely diagnosed through signs and symptoms, magnetic resonance imaging (MRI), or computed tomography (CT) findings, and medical histories; 2) patients with the first post-ischemic stroke seizure which was determined based on the definition described by Fisher et al;[@cit0028] 3) complete medical records; and 4) informed consent. Exclusion criteria included 1) patients with potential epileptogenic lesions, such as cerebral vascular malformation, cerebral hemorrhage, brain tumor, traumatic brain injury, and cortical dysplasia; 2) patients with a family history of epilepsy or patients previously diagnosed with epilepsy; and 3) patients with transient ischemic attack (TIA).

Key Definitions {#s0002-s2003}
---------------

Early onset was defined as the first post-ischemic stroke seizure occurring within 1 week after stroke insult and late onset as occurring outside 1 week. Seizure recurrence referred to the second unprovoked and separated seizure from the first one by \>24 hours. Standard EEG of 20--30 minutes duration was conducted in all 209 patients within 24--72 hours of the first post-ischemic stroke seizure onset. Abnormal EEG findings included epileptiform discharge, generalized slow, and regional slow. Partial seizures were defined as originating within networks limited to one hemisphere, and generalized seizures were defined as originating at some point within, and quickly involving, bilaterally distributed networks.

Detection of the IL-6 mRNA Expression Level {#s0002-s2004}
-------------------------------------------

The blood samples were collected after acute ischemic stroke (AIS) in all 209 patients. Total RNA was extracted from blood samples through the miRCURY^TM^ RNA Isolation kit for Biofluids (Exiqon, Vedbaek, Denmark). cDNA was then synthesized with the miRCURY LNA Universal cDNA Synthesis Kit II (Exiqon, Vedbaek, Denmark). Quantitative Real-Time PCR (qRT-PCR) was performed with the Rotor-Gene^®^ Q Real-Time Fluorescence Quantitative PCR Analyzer (Qiagen, Germany). The 2^−ΔΔCt^ method was employed to assess the IL-6 mRNA expression level using GADPH as a reference gene. The primer sequences of IL-6 were 5ʹ-ATCAGGAGACCTGCTTGATG-3ʹ (sense) and 5ʹ-TGGTGGCTTTGTCTGGATTC-3ʹ (anti-sense), and the primer sequences of GADPH were 5ʹ-AGCCTCAAGATCAGCAATG-3ʹ (sense) and 5ʹ-CACGATACCAAAGTTGTCATGGAT-3ʹ (anti-sense).

Statistical Analysis {#s0002-s2005}
--------------------

All data were statistically analyzed through the SPSS version 19.0 for Windows (SPSS Inc., USA), and significance was set at *P*\<0.05. Continuous data were validated for normality with Kolmogorov--Smirnov test. Normal data were demonstrated as mean±standard deviation (SD), and independent-samples *t*-test was used to perform univariate analysis; and non-normal data were demonstrated as median and interquartile range, and Mann--Whitney *U*-test was used to perform univariate analysis. Categorical data were demonstrated as ratios or percentages (%), and chi-square test was used to perform univariate analysis. Multivariate analysis was then conducted using a backward stepwise logistic regression model for variables with *P*\<0.10 in univariate analysis. Among the variables included in multivariate analysis, age was a continuous variable, grades of the IL-6 mRNA expression level, NIHSS scores, and lesion size were multicategorical variables, and time of seizure, seizure type, cortical involvement, gender, EEG findings, and hemorrhagic transformation were binary variables. The predictive value was assessed using a receiver operating characteristic (ROC) curve.

Results {#s0003}
=======

Demographic Data and Clinical Characteristics {#s0003-s2001}
---------------------------------------------

All 209 patients with the first post-ischemic stroke seizure included 117 (55.98%) males and 92 (44.02%) females. Their average age was 62.93±8.82 years, ranging from 37--82 years. Among them, 105 (50.24%) patients had recurrence of seizures (case group) and 104 (49.76%) patients had no recurrence (control group). The detailed demographic data and clinical characteristics are shown in [Table 1](#t0001){ref-type="table"}. According to univariate analysis ([Table 1](#t0001){ref-type="table"}), age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, and cortical involvement were statistically different between case group and control group (*P*\<0.05), and the remaining variables were not statistically different (*P*\>0.05).Table 1Demographic Data and Clinical Characteristics of Case Group and Control GroupCase Group (n=105)Control Group (n=104)*χ*^2^/*Z*/*tP*Male (n, %)65 (61.90%)52 (50.00%)3.0050.083Age (years)60.92±7.9164.96±9.743.290.002Nationalities (n, %)Han53 (50.48%)48 (46.15%)0.3910.822Uygur39 (37.14%)42 (40.38%)Other13 (12.38%)14 (13.46%)Educational level (n, %)Primary school and below26 (24.76%)29 (27.88%)0.3090.857Junior high school45 (42.86%)44 (42.31%)Senior high school and above34 (32.38%)31 (29.81%)Annual family income (RMB) (n, %)\<10,00024 (22.86%)21 (20.19%)0.4120.81410,000--20,00041 (39.05%)45 (43.27%)\>20,00045 (42.86%)48 (46.15%)Occupation (n, %)Farmer36 (34.29%)40 (38.46%)0.4390.803Worker39 (37.14%)35 (33.65%)Civil servant/teacher/doctor30 (28.57%)29 (27.88%)Smoking (n, %)33 (31.43%)30 (28.85%)0.1650.684Drinking (n, %)22 (20.95%)25 (24.04%)0.2850.593Diabetes mellitus (n, %)18 (17.14%)14 (13.46%)0.5460.46Hypertension (n, %)69 (65.71%)60 (57.69%)1.4230.233Coronary heart disease (n, %)38 (36.19%)43 (41.35%)0.5850.444Atrial fibrillation (n, %)16 (15.24%)11 (10.58%)1.0090.315TOAST classification (n, %)Large artery atherosclerosis49 (46.67%)52 (50.00%)0.897\*Cardioembolism24 (22.86%)19 (18.27%)Small vessel\
occlusion12 (11.43%)15 (14.42%)Other determined2 (1.90%)2 (1.92%)Undetermined18 (17.14%)16 (15.38%)NIHSS scores (n, %)Mild (≤8)34 (32.38%)51 (49.04%)8.7390.013Moderate (9--15)42 (40.00%)39 (37.50%)Severe (≥16)29 (27.62%)14 (13.46%)Total cholesterol (mmol/L)4.81±1.054.62±0.891.4120.158Triacylglycerol (mmol/L)1.41±0.751.33±0.600.8520.406Low density lipoprotein cholesterol (mmol/L)3.12±0.962.94±0.581.6420.132High density lipoprotein cholesterol (mmol/L)0.97±0.421.06±0.571.2980.174Status epilepticus (n, %)10 (9.52%)7 (6.73%)0.5450.614Time of seizure (n, %)Early onset41 (39.05%)58 (55.77%)5.860.019Late onset64 (60.95%)46 (44.23%)Seizure type (n, %)Generalized46 (43.81%)61 (58.65%)4.6080.032Partial59 (56.19%)43 (41.35%)EEG findings (n, %)Normal47 (44.76%)60 (57.69%)3.4960.062Abnormal58 (55.24%)44 (42.31%)Lesion size (n, %)Small12 (11.43%)28 (26.92%)8.7820.012Moderate31 (29.52%)30 (28.85%)Large62 (59.05%)46 (44.23%)Lesion location (n, %)Anterior infarct83 (79.05%)76 (73.08%)1.0230.313Posterior infarct22 (20.95%)28 (26.92%)Location of the offending lesion to different hemispheric lobes (n, %)Temporal lobes43 (40.95%)26 (25.00%)6.0120.014Frontal lobes41 (39.05%)24 (23.08%)6.2190.013Parietal lobes37 (35.24%)26 (25.00%)2.6010.109Occipital lobes34 (32.38%)27 (25.96%)1.0420.307Basal ganglia28 (26.67%)24 (23.08%)0.3600.548Thalamus20 (19.05%)18 (17.31%)0.1060.744Reperfusion therapy (n, %)35 (33.33%)25 (24.04%)2.2060.138Antiepileptic drugs (n, %)97 (92.38%)101 (97.12%)2.3490.125Hemorrhagic transformation (n, %)30 (28.57%)19 (18.27%)3.090.079Cortical involvement (n, %)46 (43.81%)29 (27.88%)5.7590.016[^1][^2]

IL-6 mRNA Expression Level {#s0003-s2002}
--------------------------

The average expression level of IL-6 mRNA was 4.87±1.91 for all 209 patients with the first post-ischemic stroke seizure, and the expression level was higher in the case group than in the control group (6.32±2.18 vs 3.41±1.64, *t*=10.912, *P*\<0.001). The expression level were then classified into four grades according to the quartiles (Q1, Q2, and Q3) of the control group. Chi-square test also demonstrated that the expression level was higher in case group than in control group ([Table 2](#t0002){ref-type="table"}).Table 2Number of Patients in Four Grades of the IL-6 mRNA Expression LevelCase Group (n=105)Control Group (n=104)*χ*^2^*P*Grade 1 \[≤Q1 (1.82)\]32649.692\<0.001Grade 2 \[\>Q1 and ≤Q2 (3.53)\]826Grade 3 \[\>Q2 and ≤Q3 (5.27)\]2226Grade 4 (\>Q3)7226

Multivariate Analysis {#s0003-s2003}
---------------------

Grades of the IL-6 mRNA expression level, age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, cortical involvement, gender, EEG findings, and hemorrhagic transformation were included in multivariate analysis. Multivariate analysis demonstrated that the IL-6 mRNA expression level was independently correlated with seizure recurrence in patients with the first post-ischemic stroke seizure after adjusting for age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, cortical involvement, gender, EEG findings, and hemorrhagic transformation ([Table 3](#t0003){ref-type="table"}).Table 3Results of Multivariate AnalysisRegression CoefficientStandard ErrorWald *χ*^2^Hazard Ratio95% Confifidence Interval*P*IL-6 mRNA expression level13.487\<0.001 Grade 20.4690.1461.0471.8590.579--4.0180.249 Grade 30.7430.2715.1184.5131.414--9.1220.021 Grade 41.2620.48925.30913.8935.071--29.948\<0.001Age−0.5060.2125.2850.6270.413--0.9140.019NIHSS scores5.4420.015 Moderate0.6320.2523.9251.6891.159--3.3760.041 Severe1.0130.4947.1842.2491.275--4.6830.009 Late onset0.7840.3215.1721.7611.183--3.5490.021 Partial seizure0.6400.2835.0351.6861.174--3.4930.023Lesion size5.8210.013 Moderate0.6450.2464.1411.7031.168--3.6210.037 Large1.0290.4487.2832.3121.328--3.5870.008Location of the offending lesion to different hemispheric lobes4.7350.028 Temporal lobes0.9120.4578.7432.4541.423--4.9740.004 Frontal lobes0.8770.4168.6692.3981.391--4.8580.005 Parietal lobes0.5720.2492.9541.5060.841--2.9830.114 Occipital lobes0.3490.1432.5061.3970.792--2.8890.158 Basal ganglia0.3510.1520.8751.1590.583--2.4680.313 Cortical involvement1.1040.4676.0281.9031.211--4.1950.011 Male0.3890.1511.9191.3980.628--2.7160.196 Hemorrhagic transformation0.4670.2132.5751.4570.830--2.7820.156 Abnormal EEG findings0.4960.2313.0891.5040.863--3.1450.123

ROC Analysis {#s0003-s2004}
------------

As shown in [Figure 1](#f0001){ref-type="fig"}, when grades of the IL-6 mRNA expression level was used to predict seizure recurrence in patients with the first post-ischemic stroke seizure, the area under the ROC curve (AUC) was 0.763 (SE=0.033, 95% CI=0.698--0.829), and the AUC adding IL-6 to the other independent variables associated with seizure recurrence was 0.820 (SE=0.029, 95% CI=0.762--0.877). When the IL-6 mRNA expression level \>Q3 (5.27) was used as the diagnosis criterion, the diagnosis results are shown in [Table 4](#t0004){ref-type="table"}. The AUC was 0.718 (SE=0.036, 95% CI=0.647--0.788). The sensitivity, specificity, accuracy, false positive rate, false negative rate, positive predictive value, and negative predictive value were 68.57%, 75.00%, 71.77%, 26.53%, 29.73%, 73.47%, and 70.27%, respectively. Therefore, its diagnostic power was moderate.Table 4Distribution Results of the IL-6 mRNA Expression Level \>Q3 in the Case Group and Control GroupCase GroupControl GroupTotal\>Q3 (5.27)722698≤Q3 (5.27)3378111Total105104209 Figure 1ROC curves of grades of the IL-6 mRNA expression level and adding IL-6 to the other independent variables in predicting seizure recurrence.

Discussion {#s0004}
==========

Inflammation after ischemic stroke is an unavoidable pathological process associated with post-ischemic injury in the brain.[@cit0029],[@cit0030] Peripheral and central inflammation can contribute to damage of the blood--brain barrier through upregulating inflammatory mediators. On the other hand, persistent inflammation can affect neuronal plasticity with network reorganization through several transcriptionally modulated mechanisms, which is potentially associated with aberrant and epileptogenic circuits.[@cit0031],[@cit0035] Seizures are well-acknowledged complications following ischemic stroke.[@cit0036],[@cit0037] Although their exact mechanism remains unknown, neurologic inflammation and damage to the blood--brain barrier are demonstrated indispensable components of epileptogenesis after brain injury.[@cit0038] Several inflammatory cytokines, such as IL-6, IL-1β, etc., have been detected in human epileptogenic tissue and cerebrospinal fluid, and, meanwhile, they have also been shown as involvements in the initiation and continuation of seizures through experimental models.

IL-6 is a pro-inflammatory cytokine and its levels are low in the central nervous system under normal conditions. However, its levels elevate significantly in many diseases, for example, stroke, epilepsy, brain damage, and so on.[@cit0039],[@cit0040] During brain inflammation, IL-6 is primarily secreted by glial cells.[@cit0041] Stimulation of microglia and astrocytes may result in increased secretion of IL-6.[@cit0042] In addition, elevated levels of other inflammatory cytokines, such as IL-1β, IL-17, TNF-α, etc., can also upregulate the expression of IL-6.[@cit0043] Fang et al[@cit0044] demonstrated that IL-6 could inhibit neuronal necrosis and apoptosis through decreasing cytosolic Ca^2+^ overload induced by N-methyl D-aspartate, implying a neuroprotection of IL-6. However, Wang et al[@cit0045] found that a chronic infusion of IL-6 could attenuate miniature excitatory postsynaptic currents regulated by N-methyl D-aspartate receptor in the hippocampal neurons of rats treated with anti-N-methyl D-aspartate receptor, which exacerbated memory impairment of rats. Therefore, IL-6 may bi-directionally impose influence on memory and synaptic plasticity.

Upregulated IL-6 levels can not only decrease hippocampal neurogenesis and long-term potentiation (LTP) but also increase gliosis and create conditions that may contribute to the onset of epilepsy.[@cit0043],[@cit0046] IL-6 can increase the blood--brain barrier permeability and has been shown as an association with development of seizures.[@cit0024],[@cit0026],[@cit0047] Ho et al[@cit0050] indicate that peripheral inflammation caused by lipopolysaccharide can increase seizure susceptibility through upregulating expression of IL-6, IL-1β, and TNF-α in the hippocampus. Erta et al[@cit0043] found that transgenic IL-6 expression is pro-convulsive in mice. Samuelsson et al[@cit0051] showed that prenatal exposure to IL-6 may lead to a higher risk of neurodegeneration of the hippocampus, inducing changes in both hippocampal morphology and structure. Pineda et al[@cit0052] report that polyinosinic-polycytidylic acid can increase IL-6 in the offspring hippocampus through inducing maternal immune activation in experimental pregnancy, eventually resulting in faster progression of epileptogenesis and hippocampal hyperexcitability in the offspring.

In summary, IL-6 levels elevate significantly after stroke, and upregulation of IL-6 may contribute to the onset of epilepsy. In this study, the incidence of post-stroke seizures was 7.02%, which was basically consistent with the result of Fu et al[@cit0053],[@cit0054] (8.1%) and higher than Kim et al (3.3%). Multivariate analysis demonstrated that the IL-6 level was independently correlated with seizure recurrence in patients with the first post-ischemic stroke seizure after adjusting for NIHSS scores and lesion size. Therefore, IL-6 does not simply mediate the association between larger/more severe AIS and recurrent seizures. In addition to IL-6, the factors associated with seizure recurrence also included age, lesion size, cortical involvement, hemorrhagic transformation, and so forth. Higher age is a protective factor, which may be correlated with smaller cerebral cortex and decreased excitability induced by degenerative changes in elderly people.[@cit0055] Cortical involvement is a recognized independent risk factor, especially the temporal and frontal lobe, which may be associated with dense cortical nerve cells with a lower threshold for seizures in this region.[@cit0056] The extravasation and stimulation of blood metabolites may have epileptogenic effects in the acute phase of stroke,[@cit0057] and so hemorrhagic transformation is a risk factor. Large lesions usually involve the temporal and frontal lobe.[@cit0056] Therefore, large lesions are also associated with seizure recurrence.

We further assessed the value of IL-6 level in predicting seizure recurrence. The results showed that the diagnostic power was moderate with sensitivity of 68.57% and specificity of 75.00%. Therefore, IL-6 might be a potential biomarker for prediction of seizure recurrence. Kim et al[@cit0054] developed a seizure recurrence risk score in the early post-stroke seizure after ischemic stroke patients. This score was based on atrial fibrillation, gender, functional disability, partial seizure type, and cortical lesion with sensitivity of 70.6% and specificity of 71.0%.

The main limitations of this study included 1) it was a retrospective analysis; 2) there was an unequivocal distribution of the follow-up period; and 3) other unknown variables, able to potentially influence the association between IL-6 and seizure recurrence, might have not been included in the analyses.

Conclusion {#s0005}
==========

IL-6 level was independently associated with seizure recurrence in patients with the first post-ischemic stroke seizure. Therefore, IL-6 might be a potential biomarker for prediction of seizure recurrence.
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[^1]: **Notes:** Lesion size: large (\>50×50 mm and \>5 slices), moderate (≤15×15 mm and \>5 slices or \>50×50 mm and ≤5 slices) and small (≤15×15 mm and ≤5 slices). \* Fisher's Exact Test.

[^2]: **Abbreviations:** TOAST, trial of org 10172 in acute stroke treatment; EEG, electroencephalography.
